Imagion Biosystems (ASX:IBX) enters trading halt ahead of breast cancer study

Imagion Biosystems (ASX:IBX) enters trading halt ahead of breast cancer study

The Market Herald Deal Room

ASX:IBX MCAP $113.9M

· Imagion Biosystems (IBX) has entered a trading halt as it plans and executes a capital raise

· The healthcare company will remain in the halt until November 23 or when the announcement is made, whichever occurs first

· In early October, Imagion received Human Research Ethics Approval (HREC) for its MagSense HER2 phase one breast cancer study

· A week later, Geoff Hollis was appointed as the company's new Chief Financial Officer, effective December 1

· He'll replace Brian Conn, who left Imagion in August to take on another full-time CFO role

· Shares in IBX last traded for 12.5 cents on November 17

Imagion Biosystems (IBX) has entered a trading halt as it plans and executes a capital raise.

The healthcare company will remain in the halt until November 23 or when the announcement is made, whichever occurs first.

Imagion is yet to announce how much it is aiming to raise or what it will use the funding for.

Read the full article on The Market Herald here